Respiri Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.19 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive RSH News and Ratings via Email

Sign-up to receive the latest news and ratings for Respiri and its competitors with MarketBeat's FREE daily newsletter.

About Respiri

Respiri Limited, an e-health SaaS company, researches, develops, and commercializes, medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include Wheezo, a mobile app, which has asthma management diary, medication usage and reminders, and symptoms and triggers to help asthma sufferers; and Wholter, a device for home ambulatory recording of nocturnal wheeze and cough. The company also offers PulmoTrack, a computerized wheeze detection product designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute asthma in the ER and ICU, and for pediatric pulmonary function testing and sleep labs. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.13 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Respiri (ASX:RSH) Frequently Asked Questions

What stocks does MarketBeat like better than Respiri?

Wall Street analysts have given Respiri a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Respiri wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Respiri's key executives?

Respiri's management team includes the following people:
  • Mr. Nicholas Smedley, Exec. Chairman
  • Mr. Marjan Mikel B.Sc., M.A.I.C.D., CEO, MD & Exec. Director
  • Dr. Samaneh Sarraf Shirazi, Chief Research Officer
  • Mr. Philippe Ludekens, Gen. Mang. of Commercial Operations
  • Mr. Peter Hildebrandt, Operations Mang.
  • Ms. Jan P. Barker, Vice-Pres of Bus. Devel.
  • Mr. Theo Antonopoulos, Chief Commercial Officer
  • Mr. Alastair Beard, Company Sec.
  • Prof. Noam Gavriely, Medical & Scientific Advisor
  • Mr. Simon Godfrey, Medical & Scientific Advisor

Who are some of Respiri's key competitors?

What is Respiri's stock symbol?

Respiri trades on the ASX under the ticker symbol "RSH."

How much money does Respiri make?

Respiri has a market capitalization of $0.00 and generates $1.39 million in revenue each year.

What is Respiri's official website?

The official website for Respiri is

How can I contact Respiri?

The company can be reached via phone at 61 3 9602 3366.

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.